Targets › RHO
3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 3; Ophthalmology; next expected readout Feb 2027.
G protein-coupled photoreceptor that activates the G protein transducin (t) signaling pathway in response to light and is essential for image-forming vision under low-light conditions. Required for postnatal photoreceptor cell viability. (UniProt, P08100)
Open in Phaseline: the race on RHO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ocugen | OCU400 Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis | RHO, NR2E3, CEP290 | Phase 3 | Retinitis Pigmentosa | Feb 2027 |
| Chigenovo Co., Ltd | ZVS203e rAAV8-delivered SauriCas9 with sgRNA targeting RHO gene mutations | RHO | Phase 1 | Retinitis Pigmentosa | Jun 2030 |
| ProQR Therapeutics | QR-1123 RNA therapeutic targeting P23H mutation in RHO gene (antisense oligonucleotide or similar | RHO | Phase 1 | Autosomal Dominant Retinitis Pigmentosa | – |
Retinitis Pigmentosa (3) Autosomal Dominant Retinitis Pigmentosa (1)
small molecule (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.